Oxford Nanopore Technologies Ltd

MinION is a pocket-sized portable device used for real-time biological analysis. It is adaptable to the analysis of DNA, RNA, or proteins. MinION's simple workflow allows end-to-end experiments in many environments.

Start using MinION

PromethION combines MinION's simplicity of use with greater workflow flexibility through scale and a modular design. Increase throughput by analysing the same sample simultaneously in multiple flow cells, or run different samples concurrently.

The GridION system, currently in development, is a scalable real-time analysis system designed to analyse single molecules such as DNA, RNA and proteins.

Metrichor provides a cloud-based platform for real time analysis of data from nanopore devices. Applications available through Metrichor will expand with the ultimate goal of enabling the analysis of any living thing, by any user, in any environment.

Start using MinION

Executive - Dr Spike Willcocks
Dr Spike Willcocks
Dr Spike Willcocks
Vice President, Business and Corporate Development
go back

After completing an MA in Chemistry and a DPhil in Biochemistry at the University of Oxford, Dr Willcocks became one of the initial members of IPGroup Plc following its landmark deal with the Chemistry Department at Oxford. Ultimately leading the Life Science team, Dr Willcocks' role encompassed all aspects of technology commercialisation, including spin-out company formation and business and corporate development, as well as private and public equity financings.

Dr Willcocks was a key player in the creation of 14 life science businesses based on technology from three universities, leading proposals for the investment of £4m in seed financing from IPGroup and holding positions of Director and Chairman for 6 portfolio companies. Working alongside the executive teams of the portfolio companies, Dr Willcocks played an integral role in out-licensing transactions, co-development deals and acquisitions. As well as supporting fundraisings for portfolio biotechnology companies, raising an aggregate of £20m, Dr Willcocks also assisted with IPGroup's own IPO in October 2003 on the LSE, raising £30m and capitalising the company at over £100m. Dr Willcocks was actively involved in the establishment of ONL whilst at IPGroup before joining full time in January 2006.

He is also a leading real tennis player, and regularly competes in international tournaments.